The United States Food and Drug Administration approved oral CSF-1R kinase inhibitor pimicotinib on November 11, 2026, for adult patients with extensive tenosynovial giant cell tumor not amenable to surgical improvement. The small molecule targets colony-stimulating factor 1 receptors responsible for driving non-malignant macrophage proliferation within synovial tissue. In pivotal multinational Phase 3 evaluations, pimicotinib demonstrated an objective response rate of 54 percent compared with 3.2 percent across control cohorts.
The global Phase 3 MANEUVER trial randomized 94 eligible patients with symptomatic tenosynovial giant cell tumor to once-daily oral pimicotinib or matched placebo across 24 weeks. Patients receiving the investigational therapy achieved statistically significant reductions in tumor volume alongside marked improvements in physical joint range of motion, and objective response metrics met primary regulatory endpoints. Principal investigator William Tap of Memorial Sloan Kettering Cancer Center reviewed trial data following federal clearance. Tap described tenosynovial giant cell tumor as rarely metastatic but locally aggressive synovial proliferation causing chronic intractable joint pain, swelling, and severe functional disability in young working-age individuals. Tap described the approval as establishing a non-surgical clinical benchmark with substantial tumor shrinkage and sustained restoration of everyday joint mobility.
Tenosynovial giant cell tumor pathobiology is driven by structural chromosomal translocations that trigger abnormal local overexpression of CSF-1, recruiting inflammatory macrophages that damage articular cartilage and bone. First-generation CSF-1R inhibitors carried boxed regulatory warnings due to severe cholestatic liver toxicity and fatal drug-induced hepatic injury. Pimicotinib was synthesized with proprietary binding conformations that optimize steric selectivity for CSF-1R while avoiding off-target interactions with related tyrosine kinases. Clinical study protocols identified no evidence of cholestatic jaundice or irreversible transaminase elevations during treatment cycles.
Post-marketing commitments finalized with the FDA require manufacturers to monitor multi-year bone mineral density metrics and cartilage biomarkers across treated patient registries.
